secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001628280-26-001909
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY
--------------------------------------------------------------------------------

- 2025 total revenue >$340M, above guided range of $327-335M.
- Q4 core test reports (DecisionDx-Melanoma, TissueCypher) +42% YoY.
- DecisionDx-Melanoma Q4: 10,022 reports; TissueCypher Q4: 11,803 reports.
- Year-end cash + marketable securities ~$300M.
- AdvanceAD-Tx launched Nov 2025; >50% of initial clinicians ordered in first 5 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026001909/0001628280-26-001909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026001909/cstl-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer